NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-10-19
Target enrollment:
Participant gender:
Summary
This research study is studying a drug combination of nivolumab and ipilimumab as a possible
treatment for hypermutated HER2 negative breast cancer.
The drugs involved in this study are:
- Nivolumab (Opdivo ®)
- Ipilimumab (Yervoy ®)